Organs-on-Chips: a new paradigm for safety assessment of drug-induced thrombosis

Patrick Ng, Chaitra Belgur, Sonalee Barthakur, Andries D. van der Meer, Geraldine A. Hamilton, Riccardo Barrile*

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

Blood hypercoagulability and thrombosis have been observed in patients during clinical trials of candidate drugs, yet these safety risks are seldom identified during preclinical testing, leading to increased mortality and morbidity, and increased attrition rates in the clinic. Current preclinical models — standard cell cultures, flow chambers, and animal models — are often ill-equipped to predict thrombosis in the clinic. In vitro models are typically assembled without critical biomechanical forces, such as shear stress and mechanical strain, or relevant cytoarchitecture, such as interactions between different tissue types, which are essential to physiological function. In addition, animal models not only are expensive and costly but also possess inherent cross-species biological differences that are difficult, if not impossible, to reconcile for accurate human predictions. As a preclinical platform with a potentially higher predictive value, organs-on-chips are fluidic systems that reproduce organ-level function via cellular components of human origin, tissue–tissue interfaces, and dynamic mechanical forces. Compared with other current preclinical models, organs-on-chips combine the advantages of tunability and ease of biochemical, histological, and image analysis, while bypassing difficulties in cross-species translation. In this review, we delineate the limitations of current preclinical models, which are often unable to predict drug-induced thrombosis, and report some recent advancements in Organs-on-Chips technology that represent a promising alternative for modeling tissue-specific thrombotic events and derisking next-generation drug discovery.

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalCurrent Opinion in Toxicology
Volume17
Early online date21 Aug 2019
DOIs
Publication statusPublished - 1 Oct 2019

Fingerprint

Thrombosis
Safety
Animal Models
Pharmaceutical Preparations
Mechanical Stress
Thrombophilia
Drug Discovery
Animals
Cell Culture Techniques
Clinical Trials
Tissue
Technology
Morbidity
Mortality
Fluidics
Cell culture
Image analysis
Shear stress
Blood
Testing

Keywords

  • Blood vessel-chip
  • Drug induced thrombosis
  • Organ-on-Chip
  • Safety assessment of therapeutics

Cite this

Ng, Patrick ; Belgur, Chaitra ; Barthakur, Sonalee ; van der Meer, Andries D. ; Hamilton, Geraldine A. ; Barrile, Riccardo. / Organs-on-Chips : a new paradigm for safety assessment of drug-induced thrombosis. In: Current Opinion in Toxicology. 2019 ; Vol. 17. pp. 1-8.
@article{0de8b6b08f9d4f4c9beedf831484bbb5,
title = "Organs-on-Chips: a new paradigm for safety assessment of drug-induced thrombosis",
abstract = "Blood hypercoagulability and thrombosis have been observed in patients during clinical trials of candidate drugs, yet these safety risks are seldom identified during preclinical testing, leading to increased mortality and morbidity, and increased attrition rates in the clinic. Current preclinical models — standard cell cultures, flow chambers, and animal models — are often ill-equipped to predict thrombosis in the clinic. In vitro models are typically assembled without critical biomechanical forces, such as shear stress and mechanical strain, or relevant cytoarchitecture, such as interactions between different tissue types, which are essential to physiological function. In addition, animal models not only are expensive and costly but also possess inherent cross-species biological differences that are difficult, if not impossible, to reconcile for accurate human predictions. As a preclinical platform with a potentially higher predictive value, organs-on-chips are fluidic systems that reproduce organ-level function via cellular components of human origin, tissue–tissue interfaces, and dynamic mechanical forces. Compared with other current preclinical models, organs-on-chips combine the advantages of tunability and ease of biochemical, histological, and image analysis, while bypassing difficulties in cross-species translation. In this review, we delineate the limitations of current preclinical models, which are often unable to predict drug-induced thrombosis, and report some recent advancements in Organs-on-Chips technology that represent a promising alternative for modeling tissue-specific thrombotic events and derisking next-generation drug discovery.",
keywords = "Blood vessel-chip, Drug induced thrombosis, Organ-on-Chip, Safety assessment of therapeutics",
author = "Patrick Ng and Chaitra Belgur and Sonalee Barthakur and {van der Meer}, {Andries D.} and Hamilton, {Geraldine A.} and Riccardo Barrile",
year = "2019",
month = "10",
day = "1",
doi = "10.1016/j.cotox.2019.08.004",
language = "English",
volume = "17",
pages = "1--8",
journal = "Current Opinion in Toxicology",
issn = "2468-2020",
publisher = "Elsevier",

}

Organs-on-Chips : a new paradigm for safety assessment of drug-induced thrombosis. / Ng, Patrick; Belgur, Chaitra; Barthakur, Sonalee; van der Meer, Andries D.; Hamilton, Geraldine A.; Barrile, Riccardo.

In: Current Opinion in Toxicology, Vol. 17, 01.10.2019, p. 1-8.

Research output: Contribution to journalReview articleAcademicpeer-review

TY - JOUR

T1 - Organs-on-Chips

T2 - a new paradigm for safety assessment of drug-induced thrombosis

AU - Ng, Patrick

AU - Belgur, Chaitra

AU - Barthakur, Sonalee

AU - van der Meer, Andries D.

AU - Hamilton, Geraldine A.

AU - Barrile, Riccardo

PY - 2019/10/1

Y1 - 2019/10/1

N2 - Blood hypercoagulability and thrombosis have been observed in patients during clinical trials of candidate drugs, yet these safety risks are seldom identified during preclinical testing, leading to increased mortality and morbidity, and increased attrition rates in the clinic. Current preclinical models — standard cell cultures, flow chambers, and animal models — are often ill-equipped to predict thrombosis in the clinic. In vitro models are typically assembled without critical biomechanical forces, such as shear stress and mechanical strain, or relevant cytoarchitecture, such as interactions between different tissue types, which are essential to physiological function. In addition, animal models not only are expensive and costly but also possess inherent cross-species biological differences that are difficult, if not impossible, to reconcile for accurate human predictions. As a preclinical platform with a potentially higher predictive value, organs-on-chips are fluidic systems that reproduce organ-level function via cellular components of human origin, tissue–tissue interfaces, and dynamic mechanical forces. Compared with other current preclinical models, organs-on-chips combine the advantages of tunability and ease of biochemical, histological, and image analysis, while bypassing difficulties in cross-species translation. In this review, we delineate the limitations of current preclinical models, which are often unable to predict drug-induced thrombosis, and report some recent advancements in Organs-on-Chips technology that represent a promising alternative for modeling tissue-specific thrombotic events and derisking next-generation drug discovery.

AB - Blood hypercoagulability and thrombosis have been observed in patients during clinical trials of candidate drugs, yet these safety risks are seldom identified during preclinical testing, leading to increased mortality and morbidity, and increased attrition rates in the clinic. Current preclinical models — standard cell cultures, flow chambers, and animal models — are often ill-equipped to predict thrombosis in the clinic. In vitro models are typically assembled without critical biomechanical forces, such as shear stress and mechanical strain, or relevant cytoarchitecture, such as interactions between different tissue types, which are essential to physiological function. In addition, animal models not only are expensive and costly but also possess inherent cross-species biological differences that are difficult, if not impossible, to reconcile for accurate human predictions. As a preclinical platform with a potentially higher predictive value, organs-on-chips are fluidic systems that reproduce organ-level function via cellular components of human origin, tissue–tissue interfaces, and dynamic mechanical forces. Compared with other current preclinical models, organs-on-chips combine the advantages of tunability and ease of biochemical, histological, and image analysis, while bypassing difficulties in cross-species translation. In this review, we delineate the limitations of current preclinical models, which are often unable to predict drug-induced thrombosis, and report some recent advancements in Organs-on-Chips technology that represent a promising alternative for modeling tissue-specific thrombotic events and derisking next-generation drug discovery.

KW - Blood vessel-chip

KW - Drug induced thrombosis

KW - Organ-on-Chip

KW - Safety assessment of therapeutics

UR - http://www.scopus.com/inward/record.url?scp=85072579013&partnerID=8YFLogxK

U2 - 10.1016/j.cotox.2019.08.004

DO - 10.1016/j.cotox.2019.08.004

M3 - Review article

AN - SCOPUS:85072579013

VL - 17

SP - 1

EP - 8

JO - Current Opinion in Toxicology

JF - Current Opinion in Toxicology

SN - 2468-2020

ER -